palmitoylethanolamide.com.au
HomeResearchMassimo 2016

Palmitoylethanolamide reduces inflammation and itch in a mouse model of contact allergic dermatitis

Massimo Vaia, Stefania Petrosino, Daniele De Filippis, Luana Negro, Andrea Guarino, Rosa Carnuccio, Vincenzo Di Marzo, Teresa Iuvone. Eur J Pharmacol. 2016 Nov 15;791:669-674.

Laboratory studyOther animals

Design
Laboratory study
Subjects
Female C57BL/6J mice with DNFB-induced contact allergic dermatitis (CAD)
Dose used in the study
PEA 5 mg/kg intraperitoneally, at each of three allergen challenges and for two more days
Duration
19-day sensitization/challenge protocol, itch assessed 48 hours after the final challenge
What was measured
Ear thickness increase, mast cell numbers, VEGF/Flk-1 expression, scratching behaviour, and the roles of CB2 and PPAR-alpha receptors.

What the authors reported

PEA reduced the ear thickness increase, mast cell numbers, and VEGF/Flk-1 expression in the late stage of contact allergic dermatitis, and reduced scratching 48 hours after the final challenge. The anti-inflammatory effect was reversed by a CB2 antagonist but not a PPAR-alpha antagonist; the anti-itch effect was reversed by both.

Limits of this study

A mouse model of contact allergic dermatitis; it cannot show effect in people. Funding and conflicts not stated in the abstract.

Source

PubMed 27720681 · doi:10.1016/j.ejphar.2016.10.005

Entry checked against the abstract on PubMed on 2026-09-22. The dose shown is the dose the researchers used. It is not a recommendation. How to read this page.